ArticleCureus2025
Diagnostic Value of Fecal Lactoferrin in Differentiating Inflammatory Bowel Disease From Irritable Bowel Syndrome: A Comparative Study in a Bangladeshi Cohort.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- A cross-sectional study reveals complex associations between gastrointestinal parasite composition and faecal immune and inflammatory biomarkers in wildlife and livestock in Kenya.Frontiers in immunology · 2026Article
- The Roles of Four Neutrophil-Derived Proteins as Non-Invasive Biomarkers in the Assessment of Inflammatory Bowel Disease.Journal of inflammation research · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) share overlapping symptoms, making differentiation challenging. IBD, which includes ulcerative colitis (UC) and Crohn's disease (CD), involves chronic inflammation requiring long-term management, whereas IBS is a functional gastrointestinal disorder without organic pathology. Fecal lactoferrin, a biomarker of intestinal inflammation, has emerged as a potential noninvasive diagnostic tool for distinguishing IBD from IBS. Objective This study aimed to measure and compare fecal lactoferrin levels in patients with IBD, IBS, and healthy controls to evaluate its diagnostic accuracy in differentiating IBD from IBS in a resource-limited setting. Methods A cross-sectional comparative study was conducted at the Department of Gastroenterology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh, from January 2016 to June 2017. The study included 50 diagnosed IBD patients, 25 IBS patients (based on Rome III criteria), and 25 healthy controls. Fecal lactoferrin levels were measured using enzyme-linked immunosorbent assay (ELISA), with a cutoff value of 7.75 µg/g considered indicative of intestinal inflammation. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. Data were analyzed using IBM SPSS Statistics for Windows, Version 25 (Released 2017; IBM Corp., Armonk, New York, United States), with statistical significance set at p < 0.05. Results The mean fecal lactoferrin levels were significantly higher in IBD patients (83.01 ± 48.54 µg/g) compared to IBS patients (6.39 ± 2.69 µg/g) and healthy controls (6.80 ± 2.30 µg/g) (p < 0.001). At a cutoff of 7.75 µg/g, fecal lactoferrin demonstrated 88% sensitivity, 84% specificity, 92% PPV, and 78% NPV in distinguishing IBD from IBS. The area under the receiver operating characteristic (ROC) curve was 0.908, indicating excellent diagnostic performance. Conclusion Fecal lactoferrin is a highly sensitive and specific biomarker for differentiating IBD from IBS. Its use as a noninvasive diagnostic tool could reduce unnecessary endoscopic procedures and aid in early and accurate diagnosis, particularly in resource-limited settings like Bangladesh. Further large-scale studies are recommended to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.